Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry Krum

Showing results (61-70 of 421) with videos related to

Pageof 43
Sort By:
British Journal of Clinical Pharmacology|July 4, 2013
Renal sympathetic nerve ablation for treatment-resistant hypertensionHenry Krum, Markus Schlaich, Paul Sobotka
European Journal of Heart Failure|January 24, 2014
Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunctionHannah Clark, Henry Krum, Ingrid Hopper
Peptides|October 5, 2007
Increased circulating urotensin II in cirrhosis: potential implications in liver diseaseWilliam Kemp, Stuart Roberts, Henry Krum
Australian Family Physician|March 3, 2004
Bush telegraph. Improving outcomes for rural and remote patients with chronic heart failureHenry Krum, Andrew Tonkin, Leon Piterman
Current Vascular Pharmacology|April 28, 2005
Urotensin II: a vascular mediator in health and diseaseWilliam Kemp, Stuart Roberts, Henry Krum
Hypertension (Dallas, Tex. : 1979)|March 19, 2002
Effect of endothelin blockade on basal and stimulated forearm blood flow in patients with essential hypertensionPaul Martin, Daniel Ninio, Henry Krum
Cardiovascular Drugs and Therapy|December 11, 2012
RAAS inhibitors and cardiovascular protection in large scale trialsThomas G von Lueder, Henry Krum
Current Opinion in Investigational Drugs (London, England : 2000)|May 15, 2003
Eplerenone. PharmaciaDanny Liew, Jennifer Martin, Henry Krum
Heart (British Cardiac Society)|May 11, 2012
Current modalities for invasive and non-invasive monitoring of volume status in heart failureThomas G von Lueder, Henry Krum
Circulation|August 17, 2005
To the heart of the matter: coxibs, smoking, and cardiovascular riskMatthias Hermann, Henry Krum, Frank Ruschitzka
Pageof 43

Showing results (61-70 of 421) with videos related to

Sort By:
Pageof 43
British Journal of Clinical Pharmacology|July 4, 2013
Renal sympathetic nerve ablation for treatment-resistant hypertensionHenry Krum, Markus Schlaich, Paul Sobotka
European Journal of Heart Failure|January 24, 2014
Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunctionHannah Clark, Henry Krum, Ingrid Hopper
Peptides|October 5, 2007
Increased circulating urotensin II in cirrhosis: potential implications in liver diseaseWilliam Kemp, Stuart Roberts, Henry Krum
Australian Family Physician|March 3, 2004
Bush telegraph. Improving outcomes for rural and remote patients with chronic heart failureHenry Krum, Andrew Tonkin, Leon Piterman
Current Vascular Pharmacology|April 28, 2005
Urotensin II: a vascular mediator in health and diseaseWilliam Kemp, Stuart Roberts, Henry Krum
Hypertension (Dallas, Tex. : 1979)|March 19, 2002
Effect of endothelin blockade on basal and stimulated forearm blood flow in patients with essential hypertensionPaul Martin, Daniel Ninio, Henry Krum
Cardiovascular Drugs and Therapy|December 11, 2012
RAAS inhibitors and cardiovascular protection in large scale trialsThomas G von Lueder, Henry Krum
Current Opinion in Investigational Drugs (London, England : 2000)|May 15, 2003
Eplerenone. PharmaciaDanny Liew, Jennifer Martin, Henry Krum
Heart (British Cardiac Society)|May 11, 2012
Current modalities for invasive and non-invasive monitoring of volume status in heart failureThomas G von Lueder, Henry Krum
Circulation|August 17, 2005
To the heart of the matter: coxibs, smoking, and cardiovascular riskMatthias Hermann, Henry Krum, Frank Ruschitzka
Pageof 43